Nov 17 (Reuters) – The US FDA on Tuesday granted accelerated approval to GSK’s drug for patients with an advanced form of lung cancer, whose disease has progressed after earlier treatments.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shailesh Kuber)

